Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Precigen, Inc. (NASDAQ:PGEN) have received a consensus rating of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $8.50.

Several analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research report on Wednesday, October 8th. Wall Street Zen lowered Precigen from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, HC Wainwright lifted their price target on Precigen from $8.50 to $9.00 and gave the company a “buy” rating in a report on Friday, November 14th.

Insider Activity at Precigen

In other news, Director Randal J. Kirk sold 1,900,036 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $4.18, for a total transaction of $7,942,150.48. Following the transaction, the director owned 341,189 shares in the company, valued at approximately $1,426,170.02. This trade represents a 84.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey B. Kindler sold 106,837 shares of Precigen stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $3.38, for a total transaction of $361,109.06. Following the completion of the sale, the director directly owned 346,070 shares of the company’s stock, valued at approximately $1,169,716.60. The trade was a 23.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 6,782,833 shares of company stock worth $26,765,972. Insiders own 47.10% of the company’s stock.

Hedge Funds Weigh In On Precigen

Several institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its holdings in shares of Precigen by 6.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 2,993 shares during the last quarter. Strs Ohio grew its holdings in Precigen by 6.8% during the third quarter. Strs Ohio now owns 50,400 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 3,200 shares during the last quarter. Rhumbline Advisers raised its position in shares of Precigen by 3.7% in the second quarter. Rhumbline Advisers now owns 198,078 shares of the biotechnology company’s stock valued at $281,000 after purchasing an additional 7,041 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Precigen by 12.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 9,043 shares during the period. Finally, Raymond James Financial Inc. lifted its stake in shares of Precigen by 59.6% in the third quarter. Raymond James Financial Inc. now owns 28,169 shares of the biotechnology company’s stock worth $93,000 after buying an additional 10,520 shares during the last quarter. 33.51% of the stock is currently owned by institutional investors.

Precigen Stock Performance

Shares of PGEN opened at $4.16 on Monday. The company has a market capitalization of $1.47 billion, a PE ratio of -2.99 and a beta of 1.16. The company has a debt-to-equity ratio of 2.22, a quick ratio of 3.95 and a current ratio of 4.04. The company’s 50 day moving average price is $3.99 and its 200 day moving average price is $3.16. Precigen has a 52 week low of $0.69 and a 52 week high of $5.22.

Precigen (NASDAQ:PGEN) last released its earnings results on Thursday, November 13th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). Precigen had a positive return on equity of 1,066.10% and a negative net margin of 3,912.92%.The company had revenue of $2.92 million during the quarter, compared to analysts’ expectations of $0.67 million. Research analysts expect that Precigen will post -0.32 EPS for the current fiscal year.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.